{"id":47238,"date":"2022-08-12T12:01:38","date_gmt":"2022-08-12T10:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tardive-dyskinesia-td-treatment-drugs-market-report-2022-size-market-share-application-analysis-regional-outlook-growth-trends-key-players-competitive-strategies-and-forecasts-to-2029-resea\/"},"modified":"2022-08-12T12:01:38","modified_gmt":"2022-08-12T10:01:38","slug":"tardive-dyskinesia-td-treatment-drugs-market-report-2022-size-market-share-application-analysis-regional-outlook-growth-trends-key-players-competitive-strategies-and-forecasts-to-2029-resea","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tardive-dyskinesia-td-treatment-drugs-market-report-2022-size-market-share-application-analysis-regional-outlook-growth-trends-key-players-competitive-strategies-and-forecasts-to-2029-resea\/","title":{"rendered":"Tardive Dyskinesia (TD) Treatment Drugs Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts to 2029 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Tardive Dyskinesia (TD) Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nTardive dyskinesia (TD) is a rare neurological disorder due to long term use of antipsychotic medications which act on dopamine receptors. It is anticipated that the TD treatment drugs market will show significant market growth over the forecast period owing to some factors such as increasing prevalence of TD, higher number of unmet needs for treatment of TD and expected launch of pipeline drug.\n<\/p>\n

\nAlthough there are various drugs used in treatment of TD, presently only Valbenazine and Deutetrabenazine are approved by the FDA. Other drugs such as benzodiazepines, botulinum toxin, amantadine, dopamine-depleting agents and calcium channel blockers etc. are also used in symptomatic relief from TD.\n<\/p>\n

\nThe report includes in-depth analysis of TD treatment drugs market for period from 2020 to 2029. For the detailed market study, TD treatment drugs market is categorized on the basis of drug types: Valbenazine, Deutetrabenazine and other drugs (benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc.)\n<\/p>\n

\nWith a view to present in-depth geographical study, the global TD treatment drugs market is segmented on the basis of key regional markets such as North America, Europe, Latin America, Asia Pacific and Middle East and Africa. For country level analysis, TD treatment drugs market is segmented into Canada, United States, United Kingdom, Germany, rest of Europe, Mexico, Brazil, Rest of Latin America, China, Japan, rest of Asia Pacific, GCC and rest of Middle East and Africa.\n<\/p>\n

\nThis report covers detailed study of qualitative information along with statistical data for better understanding of the current market situation and future market scenario. For better understanding about the ongoing market trends and future market prospects, in-depth information about the market drivers, opportunities and challenges of global TD treatment drugs market are covered in report. Attractive investment propositions and company profiling section provide detail information about the key players involved in global TD treatment drugs market.\n<\/p>\n

\nBased on drug types, the global tardive dyskinesia (TD) treatment drugs market is segmented as follows:<\/strong>\n<\/p>\n